Axsome Therapeutics(US:AXSM) Financial Modeling Prep·2025-12-05 06:05Core Insights - Axsome Therapeutics, Inc. is focused on developing therapies for central nervous system disorders, particularly in treating depression and migraines, highlighting its commitment to addressing unmet medical needs in the healthcare sector [1] Company Developments - On December 4, 2025, CEO Herriot Tabuteau sold 10,558 shares of Axsome's common stock at $148.18 each, retaining 7,229 shares post-sale, indicating continued vested interest in the company's future [2] - Axsome showcased its progress at the Piper Sandler 37th Annual Healthcare Conference, emphasizing its active engagement with the healthcare community and providing a platform to highlight recent developments [3] Market Performance - AXSM's stock is currently priced at $148.04, reflecting a slight increase of 0.16% from the previous session, with fluctuations between a low of $147.56 and a high of $149.59 today [4] - The company's market capitalization stands at approximately $7.46 billion, indicating its substantial size within the biopharmaceutical industry, with a trading volume of 351,301 shares on NASDAQ, showcasing active investor interest [5]